HSBC loses conviction in leading drugmaker, forecasts 'tough path' ahead
HSBC has lost conviction in its buy rating for AstraZeneca, a British-Swedish drugmaker, after a rare clinical trial failure.
Reported by 1 outlet — CNBC Top News. See all sources ↓
HSBC has stopped believing in AstraZeneca's stock. AstraZeneca is a big drug company. It made a mistake in a test for a heart disease.
Why it matters
This change affects AstraZeneca's stock price and investors who believe in the company.
- What happened to AstraZeneca's stock?
- HSBC lost conviction in its buy rating for AstraZeneca.
- Why did HSBC change its opinion?
- AstraZeneca made a rare clinical trial failure that sent shares tumbling.
- What is a clinical trial?
- A clinical trial is a test to see if a new medicine works and is safe.
How outlets are framing the same story
These are the main editorial angles found across reporting. Use them to quickly compare what different outlets emphasize, omit, or question.
The outlets frame the story as a change in HSBC's opinion about AstraZeneca's stock, with some outlets focusing on the impact on the company's stock price.
- Coverage cardFraming signal1AngleScouting report
Impact on stock price
Sources3TypeAngleCNBCHow the change affects AstraZeneca's stock priceHSBCThe bank's analysts downgraded the stockOther outletsOther outlets may focus on the impact on investors - Coverage cardFraming signal2AngleScouting report
Clinical trial failure
Sources3TypeAngleCNBCA rare clinical trial failure that sent shares tumblingHSBCAstraZeneca made a rare clinical trial failureOther outletsOther outlets may focus on the details of the trial - Coverage cardFraming signal3AngleScouting report
HSBC's change in opinion
Sources3TypeAngleCNBCHSBC lost conviction in its buy rating for AstraZenecaHSBCThe bank's analysts have downgraded the stockOther outletsOther outlets may focus on the reasons behind the change